Combined treatment with growth hormone and luteinizing hormone releasing hormone-analogue (LHRHa) of pubertal children with familial short stature.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The researchers evaluated the 12 month growth of 18 pubertal children with familial short stature randomly assigned to clinical follow-up (group A), GH treatment alone (group B) and GH+LHRH analogue (LHRHa) treatment (group C).

Who Took Part

The abstract describes 18 children taking part.

The age groups tagged for this paper are children and teenagers, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

What Was Measured

The researchers evaluated the 12 month growth of 18 pubertal children with familial short stature randomly assigned to clinical follow-up (group A), GH treatment alone (group B) and GH+LHRH analogue (LHRHa) treatment (group C).

The subject headings attached to it are Body Height, Dwarfism, Follicle Stimulating Hormone, Gonadotropin-Releasing Hormone, Growth Hormone, Kidney Function Tests and Liver Function Tests.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.